Radiopharm Theranostics Ltd (ASX:RAD) has tapped Dr Sherin Al-Safadi – developer of a “world-class” platform of radiopharmaceutical products for both diagnostic and therapeutic uses – for the position of vice president of Medical and Corporate Affairs.
Dr Al-Safadi most recently held the position of vice president of medical affairs at POINT Biopharma, where she assembled and led a medical affairs division and the strategic and tactical planning for Phase III support and launch preparation of radiopharmaceuticals.
She also provided strategic input and leadership for business development and licensing opportunities in that role.
She currently serves as co-founder and president at Foundation Amal (Canada-USA), where she led a successful 2021 cross-border expansion into the USA and spearheaded the development of a branding and communication strategy.
Critical success factor
"We are thrilled to have Sherin join our team at Radiopharm Theranostics," Radiopharm CEO and managing director Riccardo Canevari said.
"Her expertise and leadership skills will be invaluable as we continue to grow and develop our pipeline of radiopharmaceutical products.
“In particular, with F18-Pivalate entering late-stage development, the Medical Affairs function becomes a critical success factor.”
Dr Al-Safadi holds a PhD in Neurobiology from Concordia University, an MBA in Entrepreneurship and Management from the John Molson School of Business, and a Masters of Sciences (MSc) in Pharmacology (oncology drug development) from McGill University.